

**REMARKS**

Applicant reserves the right to prosecute non-elected subject matter in subsequent divisional applications.

Claims 2-12 and 14-23 have previously been canceled without prejudice or disclaimer.

Claims 24-26 are withdrawn from consideration.

Claims 1, 2, 13, and new claim 27 are under consideration in this application.

**Rejoinder of Method Claims**

Claims 24-26 are “method of use” claims that cover the same scope of product as the product claims under consideration. Therefore, upon allowance of any of the product claims, it is submitted that claims 24-26 should be rejoined and considered, in accordance with the Commissioner’s Notice in the Official Gazette of March 26, 1996, entitled “Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b).”

**Amendment to the Specification**

Applicants request the removal from the specification of the source of the TONGTUT01 cDNA library, “(specimen #0065B; Mayo Clinic, Rochester MN)” This request is made pursuant to an agreement reached between the Mayo Clinic and Applicants’ assignee, Incyte Pharmaceuticals, Inc. (now Incyte Corp.). That agreement requires Applicants’ assignee to omit any reference to the Mayo Clinic in any of its patent applications, or else be subject to suit by the Mayo Clinic.

Applicants respectfully note that the requested ***deletion*** from the Specification of reference to the Mayo Clinic is not an introduction of “new matter” as alleged by the Examiner (See Final Office Action, mailed July 1, 2003, page 2), and respectfully request the Examiner to cite the section(s) of the statute, rules, and/or MPEP which supports the Examiner’s allegations. Otherwise, Applicants request entry of the amendment to the Specification as requested in the response filed December 9, 2002, as no new matter is added by said amendment.

**Amendments to the Claims**

Claim 27 has been added in order to further define the claimed invention. In particular, claim 1 a) as added recites “a polypeptide comprising an amino acid sequence of SEQ ID NO:1,” Support for claim 37 a) can be found in original claim 1 as filed.

Claim 27 b) as added recites “a polypeptide comprising a naturally occurring an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1,” Support for claim 27 b) can be found throughout the specification, e.g., original claim 2, and page 11, lines 26-29.

Claim 27 c) as added recites “a biologically active fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1 wherein the biological activity is IL2 inducing activity.” Support for claim 27 c) can be found throughout the specification, e.g., page 7, lines 12-16; page 8, lines 24-26. Support for the functional limitation can be found throughout the Specification, for example, at page 50, Example X which describes an assay for measuring IL-2 induction in a cell transformed with TCRLP.

Claim 27 d) as added recites “an immunogenic fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1.” Support for claim 27 d) can be found throughout the specification, e.g., page 7, lines 12-16; page 8, lines 8-14; page 8, lines 25-28.

No new matter is added by these amendments. It is believed that entry of the requested amendments is proper.

**I. Applicants’ Maintain That Utilities for Applicant’s Polypeptides Were Well-Established Prior to Applicant’s Filing Date**

As a preliminary matter, Applicant’s arguments, supporting evidence and the Declaration of Lars Michael Furness as submitted October 1, 2001 and arguments and evidence submitted by Applicants on December 9, 2002, and November 3, 2003, are incorporated herein as if reiterated in full.

The following arguments and references corroborate Applicant's previous assertions that the claimed invention has utilities which show the 'well-established' nature of these utilities prior to Applicant's priority date, July 18, 1997.

In particular, Applicant submits two expert Declarations under 37 C.F.R. § 1.132, with respective attachments, and five (5) scientific references. The Rockett Declaration, Iyer Declaration, and the five (5) references fully establish that, prior to the July 18, 1997 filing date of the parent application (U.S. Serial No. 08/897,097, hereinafter the "Hillman '097" application), now U.S. Patent No. 6,054,292, issued on April 25, 2000, it was well-established in the art that:

expression analysis is useful, *inter alia*, in drug discovery and lead optimization efforts; in toxicology, particularly toxicology studies conducted early in drug development efforts; and in phenotypic characterization and categorization of cell types, including neoplastic cell types;

expression analysis can be performed by measuring expression of either proteins or of their encoding transcripts;

it is not necessary that the biological function of a gene be known for measurement of its expression to be useful in drug discovery and lead optimization analyses, toxicology, or molecular phenotyping experiments;

antibodies can routinely be prepared that specifically identify the protein immunogen; used as gene expression probes, such antibodies generate a signal that is specific to the protein, that is, produce a gene-specific expression signal; [Emphasis added]

each additional gene-specific probe used as a tool in expression analysis provides an additional gene-specific signal that could not otherwise have been detected, giving a more comprehensive, robust, higher resolution, statistically more significant, and thus more useful expression pattern in such analyses than would otherwise have been possible;

biologists, such as toxicologists, recognize the increased utility of more comprehensive, robust, higher resolution, statistically more significant results, and thus want each newly identified expressed gene to be included in such an analysis;

failure of a probe to detect changes in expression of its cognate gene (because such changes did not occur in a particular experiment) does not diminish the usefulness of the probe as a research tool, because such information is itself useful; and

failure of a probe completely to detect its cognate transcript in any particular expression analysis experiment (because the protein is not normally expressed in that sample) does not deprive the probe of usefulness to the community of users who would use it as a research tool.

In order to demonstrate these points, Applicant directs the Examiner's attention to quotes from the Declarations submitted herewith, as well as documents establishing the state of the art before and around the filing date of the instant application:

"It is widely understood among molecular and cellular biologists that protein expression levels provide complementary profiles for any given cell and cellular state."<sup>1</sup>

"Thus, as with nucleic acid microarrays, the greater the number of proteins detectable, the greater the power of the technique; the absence or failure of a protein to change in expression levels does not diminish the usefulness of the method; and prior knowledge of the biological function of the protein is not required. As applied to protein expression profiling, these principles have been well understood since at least as early as the 1980s."<sup>2</sup>

"It is my opinion, therefore, based on the state of the art in toxicology at least since the mid-1990s -- and as regards protein profiling, even earlier -- that disclosure of the sequence of a new . . . protein, with or without knowledge of its biological function, would have been sufficient information for a toxicologist to use the . . . protein in expression profiling studies in toxicology."<sup>3</sup>

In his Declaration, Dr. Iyer explains why a person of skill in the art in 1997 would have understood that any expressed polynucleotide is useful for gene expression monitoring applications using cDNA microarrays, stating that "[t]o provide maximum versatility as a research tool, the microarray should include -- and as a biologist I would want my microarray to include -- each newly identified gene as a probe." (Iyer Declaration, ¶ 9.)

The Declarations being sufficiently brief, Applicant commends them in their entireties to the Examiner's attention and devote further comment here to identifying for the Examiner's convenience

---

<sup>1</sup> Declaration of John C. Rockett, ¶ 11.

<sup>2</sup> Declaration of John C. Rockett, ¶ 14.

<sup>3</sup> Declaration of John C. Rockett, ¶ 18. "Use of the words 'it is my opinion' to preface what someone of ordinary skill in the art would have known does not transform the factual statements contained in the declaration into opinion testimony." *In re Alton*, 37 USPQ2d 1578, 1583 (Fed. Cir. 1996).

certain representative passages of the references filed as part of Applicant's arguments of the well established utilities for the instantly claimed invention.

The following references establish the state of the art before and around the filing date of the instant application:

**U.S. Pat. No. 5,569,588** ("Methods for Drug Screening") ("the '588 patent"), issued October 29, 1996, with a priority date of August 1995, describes an expression profiling platform, the "genome reporter matrix," which is based upon the measurement of protein expression levels. The patent further describes use of nucleic acid microarrays to measure transcript expression levels, making clear that the utility of comparing multidimensional expression data sets equally applies to protein expression data and transcript expression data.

The patent speaks clearly to the usefulness of such expression analyses, particularly but not exclusively protein expression profiling, in drug development and toxicology, particularly pointing out that a protein's failure to change in expression level is a useful result. Thus, with emphasis added,

The invention provides "[m]ethods and compositions for modeling the transcriptional responsiveness of an organism to a candidate drug. . . . [The final step of the method comprises] comparing reporter gene product signals for each cell before and after contacting the cell with the candidate drug to obtain a drug response profile which provides a model of the transcriptional responsiveness of said organism to the candidate drug." [abstract]

"The present invention exploits the recent advances in genome science to provide for the rapid screening of large numbers of compounds against a systemic target comprising substantially all targets in a pathway [or] organism." [col. 1]

"The ensemble of reporting cells comprises as comprehensive a collection of transcription regulatory genetic elements as is conveniently available for the targeted organism so as to most accurately model the systemic transcriptional response. Suitable ensembles generally comprise thousands of individually reporting elements; preferred ensembles are substantially comprehensive, i.e. provide a transcriptional response diversity comparable to that of the target organism. Generally, a substantially comprehensive ensemble requires transcription regulatory genetic elements from at least a majority of the organism's genes, and preferably includes those of all or nearly all of the genes. We term such a substantially comprehensive ensemble a genome reporter matrix." [col. 2]

"Drugs often have side effects that are in part due to the lack of target specificity. . . . [A] genome reporter matrix reveals the spectrum of other genes in the genome also affected by the compound. In considering two different compounds both of which induce the ERG10 reporter, if one compound affects the expression of 5 other reporters and a second compound affects the expression of 50 other reports, the first compound is, a priori, more likely to have fewer side effects." [cols. 2 - 3]

"Furthermore, it is not necessary to know the identity of any of the responding genes." [col. 3]

"[A]ny new compound that induces the same response profile as [a] . . . dominant tubulin mutant would provide a candidate for a taxol-like pharmaceutical." [col. 4]

"The genome reporter matrix offers a simple solution to recognizing new specificities in combinatorial libraries. Specifically, pools of new compounds are tested as mixtures across the matrix. If the pool has any new activity not present in the original lead compound, new genes are affected among the reporters." [col. 4]

"A sufficient number of different recombinant cells are included to provide an ensemble of transcriptional regulatory elements of said organism sufficient to model the transcriptional responsiveness of said organism to a drug. In a preferred embodiment, the matrix is substantially comprehensive for the selected regulatory elements, e.g. essentially all of the gene promoters of the targeted organism are included." [cols. 6 - 7]

"In a preferred embodiment, the basal response profiles are determined. . . . The resultant electrical output signals are stored in a computer memory as genome reporter output signal matrix data structure associating each output signal with the coordinates of the corresponding microtiter plate well and the stimulus or drug. This information is indexed against the matrix to form reference response profiles that are used to determine the response of each reporter to any milieu in which a stimulus may be provided. After establishing a basal response profile for the matrix, each cell is contacted with a candidate drug. The term drug is used loosely to refer to agents which can provoke a specific cellular response. . . . The drug induces a complex response pattern of repression, silence and induction across the matrix . . . . The response profile reflects the cell's transcriptional adjustments to maintain homeostasis in the presence of the drug. . . . After contacting the cells with the candidate drug, the reporter gene product signals from each of said cells is again measured to determine a stimulated response profile. The basal o[r] background response profile is then compared with . . . the stimulated response profile to identify the cellular response profile to the candidate drug." [cols. 7 - 8]

"In another embodiment of the invention, a matrix [i.e., array] of hybridization probes corresponding to a predetermined population of genes of the selected organism

is used to specifically detect changes in gene transcription which result from exposing the selected organism or cells thereof to a candidate drug. In this embodiment, one or more cells derived from the organism is exposed to the candidate drug in vivo or ex vivo under conditions wherein the drug effects a change in gene transcription in the cell to maintain homeostasis. Thereafter, the gene transcripts, primarily mRNA, of the cell or cells is isolated . . . [and] then contacted with an ordered matrix [array] of hybridization probes, each probe being specific for a different one of the transcripts, under conditions where each of the transcripts hybridizes with a corresponding one of the probes to form hybridization pairs. The ordered matrix of probes provides, in aggregate, complements for an ensemble of genes of the organism sufficient to model the transcriptional responsiveness of the organism to a drug. . . . The matrix-wide signal profile of the drug-stimulated cells is then compared with a matrix-wide signal profile of negative control cells to obtain a specific drug response profile." [col. 8]

"The invention also provides means for computer-based qualitative analysis of candidate drugs and unknown compounds. A wide variety of reference response profiles may be generated and used in such analyses." [col. 8]

"Response profiles for an unknown stimulus (e.g. new chemicals, unknown compounds or unknown mixtures) may be analyzed by comparing the new stimulus response profiles with response profiles to known chemical stimuli." [col. 9]

"The response profile of a new chemical stimulus may also be compared to a known genetic response profile for target gene(s)." [col. 9]

**WO 95/21944** ("Differentially expressed genes in healthy and diseased subjects"), published August 17, 1995, describes the use of nucleic acid microarrays in expression profiling analyses, emphasizing that *patterns* of expression can be used to distinguish healthy tissues from diseased tissues and that *patterns* of expression can additionally be used in drug development and toxicology studies, without knowledge of the biological function of the encoded gene product. In particular, and with emphasis added:

The present invention involves . . . methods for diagnosing diseases . . . characterized by the presence of [differentially expressed] . . . genes, despite the absence of knowledge about the gene or its function. The methods involve the use of a composition suitable for use in hybridization which consists of a solid surface on which is immobilized at pre-defined regions thereon a plurality of defined oligonucleotide/ polynucleotide sequences for hybridization. Each sequence comprises a fragment of an EST. . . . Differences in hybridization patterns produced through use of this composition and the specified methods enable diagnosis of diseases based on differential expression of genes of unknown function. . . . [abstract]

The method [of the present invention] involves producing and comparing hybridization patterns formed between samples of expressed mRNA or cDNA polynucleotide sequences . . . and a defined set of oligonucleotide/polynucleotide[] . . . immobilized on a support. Those defined [immobilized] oligonucleotide/polynucleotide sequences are representative of the total expressed genetic component of the cells, tissues, organs or organism as defined by the collection of partial cDNA sequences (ESTs). [page 2]

The present invention meets the unfilled needs in the art by providing methods for the . . . use of gene fragments and genes, even those of unknown full length sequence and unknown function, which are differentially expressed in a healthy animal and in an animal having a specific disease or infection by use of ESTs derived from DNA libraries of healthy and/or diseased/infected animals. [page 4]

Yet another aspect of the invention is that it provides . . . a means for . . . monitoring the efficacy of disease treatment regimes including . . . toxicological effects thereof." [page 4]

It has been appreciated that one or more differentially identified EST or gene-specific oligonucleotide/polynucleotides define a pattern of differentially expressed genes diagnostic of a predisease, disease or infective state. A knowledge of the specific biological function of the EST is not required only that the EST[] identifies a gene or genes whose altered expression is associated reproducibly with the predisease, disease or infectious state. [page 4]

As used herein, the term 'disease' or 'disease state' refers to any condition which deviates from a normal or standardized healthy state in an organism of the same species in terms of differential expression of the organism's genes. . . [whether] of genetic or environmental origin, for example, an inherited disorder such as certain breast cancers. . . [or] administration of a drug or exposure of the animal to another agent, e.g., nutrition, which affects gene expression. [page 5]

As used herein, the term 'solid support' refers to any known substrate which is useful for the immobilization of large numbers of oligonucleotide/polynucleotide sequences by any available method . . . [and includes, inter alia,] nitrocellulose, . . . glass, silica. . . [page 6]

By 'EST' or 'Expressed Sequence Tag' is meant a partial DNA or cDNA sequence of about 150 to 500, more preferably about 300, sequential nucleotides. . . . [page 6]

One or more libraries made from a single tissue type typically provide at least about 3000 different (i.e., unique) ESTs and potentially the full complement of all



possible ESTs representing all cDNAs e.g., 50,000 – 100,000 in an animal such as a human. [page 7]

The lengths of the defined oligonucleotide/ polynucleotides may be readily increased or decreased as desired or needed. . . . The length is generally guided by the principle that it should be of sufficient length to insure that it is on[] average only represented once in the population to be examined. [page 7]

Comparing the . . . hybridization patterns permits detection of those defined oligonucleotide/ polynucleotides which are differentially expressed between the healthy control and the disease sample by the presence of differences in the hybridization patterns at pre-defined regions [of the solid support]. [page 13]

It should be appreciated that one does not have to be restricted in using ESTs from a particular tissue from which probe RNA or cDNA is obtained[;] rather any or all ESTs (known or unknown) may be placed on the support. Hybridization will be used [to] form diagnostic patterns or to identify which particular EST is detected. For example, all known ESTs from an organism are used to produce a 'master' solid support to which control sample and disease samples are alternately hybridized. [page 14]

Diagnosis is accomplished by comparing the two hybridization patterns, wherein substantial differences between the first and second hybridization patterns indicate the presence of the selected disease or infection in the animal being tested. Substantially similar first and second hybridization patterns indicate the absence of disease or infection. This[, ] like many of the foregoing embodiments[, ] may use known or unknown ESTs derived from many libraries. [page 18]

Still another intriguing use of this method is in the area of monitoring the effects of drugs on gene expression, both in laboratories and during clinical trials with animal[s], especially humans. [page 18]

**WO 95/20681** ("Comparative Gene Transcript Analysis"), filed in 1994 by Applicant's assignee and published August 3, 1995, has three issued U.S. counterparts: U.S. Pat. Nos. 5,840,484, issued November 24, 1998; 6,114,114, issued September 5, 2000; and 6,303,297, issued October 16, 2001.

The specification describes the use of transcript expression *patterns*, or "images," each comprising multiple pixels of gene-specific information, for diagnosis, for cellular phenotyping, and in toxicology and drug development efforts. The specification describes a plurality of methods for

obtaining the requisite expression data -- one of which is microarray hybridization -- and equates the uses of the expression data from these disparate platforms. In particular, and with emphasis added:

The invention provides a "method and system for quantifying the relative abundance of gene transcripts in a biological specimen. . . . [G]ene transcript imaging can be used to detect or diagnose a particular biological state, disease, or condition which is correlated to the relative abundance of gene transcripts in a given cell or population of cells. The invention provides a method for comparing the gene transcript image analysis from two or more different biological specimens in order to distinguish between the two specimens and identify one or more genes which are differentially expressed between the two specimens." [abstract]

"[W]e see each individual gene product as a 'pixel' of information, which relates to the expression of that, and only that, gene. We teach herein [] methods whereby the individual 'pixels' of gene expression information can be combined into a single gene transcript 'image,' in which each of the individual genes can be visualized simultaneously and allowing relationships between the gene pixels to be easily visualized and understood." [page 2]

"The present invention avoids the drawbacks of the prior art by providing a method to quantify the relative abundance of multiple gene transcripts in a given biological specimen. . . . The method of the instant invention provides for detailed diagnostic comparisons of cell profiles revealing numerous changes in the expression of individual transcripts." [page 6]

"High resolution analysis of gene expression be used directly as a diagnostic profile. . . . " [page 7]

"The method is particularly powerful when more than 100 and preferably more than 1,000 gene transcripts are analyzed." [page 7]

"The invention . . . includes a method of comparing specimens containing gene transcripts." [page 7]

"The final data values from the first specimen and the further identified sequence values from the second specimen are processed to generate ratios of transcript sequences, which indicate the differences in the number of gene transcripts between the two specimens." [i.e., the results yield analogous data to microarrays] [page 8]

"Also disclosed is a method of producing a gene transcript image analysis by first obtaining a mixture of mRNA, from which cDNA copies are made." [page 8]

"In a further embodiment, the relative abundance of the gene transcripts in one cell type or tissue is compared with the relative abundance of gene transcript numbers

in a second cell type or tissue in order to identify the differences and similarities." [page 9]

"In essence, the invention is a method and system for quantifying the relative abundance of gene transcripts in a biological specimen. The invention provides a method for comparing the gene transcript image from two or more different biological specimens in order to distinguish between the two specimens. . . . " [page 9]

"[T]wo or more gene transcript images can be compared and used to detect or diagnose a particular biological state, disease, or condition which is correlated to the relative abundance of gene transcripts in a given cell or population of cells." [pages 9 – 10]

"The present invention provides a method to compare the relative abundance of gene transcripts in different biological specimens. . . . This process is denoted herein as gene transcript imaging. The quantitative analysis of the relative abundance for a set of gene transcripts is denoted herein as 'gene transcript image analysis' or 'gene transcript frequency analysis'. The present invention allows one to obtain a profile for gene transcription in any given population of cells or tissue from any type of organism." [page 11]

"The invention has significant advantages in the fields of diagnostics, toxicology and pharmacology, to name a few." [page 12]

"[G]ene transcript sequence abundances are compared against reference database sequence abundances including normal data sets for diseased and healthy patients. The patent has the disease(s) with which the patient's data set most closely correlates." [page 12]

"For example, gene transcript frequency analysis can be used to different normal cells or tissues from diseased cells or tissues. . . ." [page 12]

"In toxicology, . . . [g]ene transcript imaging provides highly detailed information on the cell and tissue environment, some of which would not be obvious in conventional, less detailed screening methods. The gene transcript image is a more powerful method to predict drug toxicity and efficacy. Similar benefits accrue in the use of this tool in pharmacology. . . . [page 12]

"In an alternative embodiment, comparative gene transcript frequency analysis is used to differentiate between cancer cells which respond to anti-cancer agents and those which do not respond." [page 12]

"In a further embodiment, comparative gene transcript frequency analysis is used . . . for the selection of better pharmacologic animal models." [page 14]

"In a further embodiment, comparative gene transcript frequency analysis is used in a clinical setting to give a highly detailed gene transcript profile of a diseased state or condition." [page 14]

"An alternate method of producing a gene transcript image includes the steps of obtaining a mixture of test mRNA and providing a representative array of unique probes whose sequences are complementary to at least some of the test mRNAs. Next, a fixed amount of the test mRNA is added to the arrayed probes. The test mRNA is incubated with the probes for a sufficient time to allow hybrids of the test mRNA and probes to form. The mRNA-probe hybrids are detected and the quantity determined." [page 15]

"[T]his research tool provides a way to get new drugs to the public faster and more economically." [page 36]

"In this method, the particular physiologic function of the protein transcript need not be determined to qualify the gene transcript as a clinical marker." [page 38]

"[T]he gene transcript changes noted in the earlier rat toxicity study are carefully evaluated as clinical markers in the followed patients. Changes in the gene transcript image analyses are evaluated as indicators of toxicity by correlation with clinical signs and symptoms and other laboratory results. . . . The . . . analysis highlights any toxicological changes in the treated patients." [page 39]

In light of this and other evidence of the state of the art, one of ordinary skill in the toxicology arts would conclude that "[i]t is my opinion, therefore, based on the state of the art in toxicology at least since the mid-1990s -- and as regards protein profiling, even earlier -- that disclosure of the sequence of a new gene or protein, with or without knowledge of its biological function, would have been sufficient information for a toxicologist to use the gene and/or protein in expression profiling studies in toxicology."<sup>4</sup>

## **II. Applicant's Evidence of at Least One Utility for the Claimed Invention Establishes That Applicant's Invention Has "Specific Utility"**

Applicant is demonstrating that, *regardless* of the specific functional properties of the claimed

---

<sup>4</sup> Declaration of Dr. John C. Rockett, ¶ 18.

invention, the utility of Applicant's claimed polypeptides depends instead upon the structural properties that allow them specifically to be identified, for example, by specific antibodies or by 2D PAGE and mass spectroscopy sequencing of spots on the gel -- that is, the amino acid sequences of the polypeptide.

**III. Applicant's Evidence of at Least One Utility for the Claimed Invention Establishes That Applicant's Invention has Utility Beyond Expression Analysis**

Applicant has submitted facts and evidence in their response filed November 3, 2003 which showed that the utility of the claimed TCRLP polypeptides is not limited to said polypeptides merely serving as a component of an assay for monitoring gene expression. Applicants' facts show, in particular: (1) how persons of ordinary skill in the art would have known to use, and would have known *how* to use, TCRLP polypeptides as disease markers for cancers, particularly T-cell leukemias and T-cell lymphomas and for other uses, regardless of the polypeptide's biological function; (2) the skilled artisan would have known to use, and *how* to use data generated by expression analysis using the TCRLP polypeptides for toxicology assessments, in drug development, and for molecular phenotyping (TCRLP likely maps to the T cell receptor beta subunit gene cluster on chromosome 7), not withstanding the polypeptide's biological function; and (3) that the uses for both the TCRLP polypeptides are not limited to expression analysis. Thus, Applicant's TCRLP polypeptides are patentably useful. See, for example, the Rockett Declaration, ¶ 18.

**IV. Utility of the TCRLP Polypeptides in Assays Discussed Above Provides Sufficient Utility Under 35 U.S.C. § 101**

The Court of Appeals for the Federal Circuit has made clear that an invention is useful if it provides an identifiable benefit. The identified benefit, regardless of magnitude, would assuredly suffice under 35 U.S.C. § 101.

An invention is "useful" under section 101 if it is capable of providing some identifiable benefit. See *Brenner v. Manson*, 383 U.S. 519, 534 [148 USPQ 689] (1966); *Brooktree Corp. v. Advanced Micro Devices, Inc.*, 977 F.2d 1555, 1571 [24 USPQ2d 1401] (Fed. Cir. 1992) ("to violate Section 101 the claimed device must be totally incapable of achieving a useful result") [emphasis added]; *Fuller v. Berger*,

120 F. 274, 275 (7<sup>th</sup> Cir. 1903) (test for utility is whether invention "is incapable of serving any beneficial end").

*Juicy Whip v. Orange Bang Inc.*, 51 USPQ2d 1700 (Fed. Cir. 1999). "[T]he fact that an invention has only limited utility and is only operable in certain applications is not grounds for finding lack of utility." *Envirotech Corp. v. Al George, Inc.*, 730 F.2d 753, 762, 221 USPQ 473, 480 (Fed. Cir. 1984), quoted in *Stiftung v. Renishaw PLC*, 945 F.2d 1173, 1180, 20 USPQ2d 1094 (Fed. Cir. 1991).

## **V. Summary**

Applicant respectfully submits that the filing of this request for Continued Examination (RCE) application will compel the Office to give full consideration to the arguments and evidence presented in the response filed November 3, 2003. Additionally, the facts are fully sufficient to support a finding that the TCRLP polypeptides as used in protein expression monitoring will be found to have well-established utilities, any one of which is sufficient to satisfy 35 U.S.C. §§ 101 and 112, first paragraph, and overcome the rejections of claims 1, 2 and 13 under 35 U.S.C. §§ 101 and 112, first paragraph. Therefore, Applicant respectfully requests reconsideration and withdrawal of these grounds of rejection.

**CONCLUSION**

In light of the above amendments and remarks, Applicant submits that the present application is fully in condition for allowance, and request that the Examiner withdraw the outstanding objections/rejections. Early notice to that effect is earnestly solicited.

If the Examiner contemplates other action, or if a telephone conference would expedite allowance of the claims, Applicant invites the Examiner to contact the undersigned at the number listed below.

Please charge Deposit Account No. **09-0108** in the amount of **\$770.00** for the filing of this Request for Continued Examination (RCE) application and **\$110.00** for a one (1) month extension of time as set forth in the enclosed fee transmittal letter. If the USPTO determines that an additional fee is necessary, please charge any required fee to Deposit Account No. 09-0108.

Respectfully submitted,  
INCYTE CORPORATION

Date:

06, February 2003

Shirley A. Recipon  
Shirley A. Recipon  
Reg. No. 47,016  
Direct Dial Telephone: (650) 621-8555

Date:

06 February 2003

Cathleen M. Rocco  
Cathleen M. Rocco  
Reg. No. 46,172  
Direct Dial Telephone: (650) 845-4587

**Customer No.: 27904**  
3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 849-8886

Attachment(s):

- A: WO 95/21944, SmithKline Beecham, "Differentially expressed genes in healthy and diseased subjects" (Aug. 17, 1995)
- B: WO 95/20681, Incyte Pharmaceuticals, "Comparative Gene Transcript Analysis" (Aug 3, 1995)
- C: Schena et al., "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray," Science 270:467-470 (Oct 20, 1995)
- D: U.S. Pat. No. 5,569,588 ("Methods for Drug Screening") ("the '588 patent"), issued October 29, 1996
- E: WO 95/35505, Stanford University, "Method and apparatus for fabricating microarrays of biological samples" (Dec 28, 1995)
- Declaration of John C. Rockett, Ph.D., under 37 C.F.R. § 1.132, with Exhibits A - Q
- Declaration of Vishwanath R. Iyer, Ph.D., under 37 C.F.R. § 1.132 with Exhibits A - E